Virtu Financial LLC Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Virtu Financial LLC acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 66,441 shares of the company’s stock, valued at approximately $662,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Recursion Pharmaceuticals by 37.7% during the 3rd quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company’s stock worth $118,627,000 after purchasing an additional 4,247,002 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Recursion Pharmaceuticals by 360.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 24,091 shares of the company’s stock worth $238,000 after buying an additional 18,854 shares during the last quarter. Arizona State Retirement System boosted its position in Recursion Pharmaceuticals by 8.5% during the 4th quarter. Arizona State Retirement System now owns 39,926 shares of the company’s stock valued at $394,000 after purchasing an additional 3,125 shares during the period. International Assets Investment Management LLC lifted its position in Recursion Pharmaceuticals by 1,423.8% in the 4th quarter. International Assets Investment Management LLC now owns 16,762 shares of the company’s stock valued at $1,700,000 after purchasing an additional 15,662 shares during the last quarter. Finally, Cherry Creek Investment Advisors Inc. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $176,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on RXRX shares. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Needham & Company LLC reiterated a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $8.42, for a total transaction of $421,000.00. Following the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at approximately $6,388,573.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $8.42, for a total value of $421,000.00. Following the transaction, the chief executive officer now owns 758,738 shares in the company, valued at $6,388,573.96. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Tina Marriott sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.78, for a total transaction of $26,340.00. Following the sale, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $4,701,312.46. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 202,235 shares of company stock valued at $1,654,400. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Trading Down 4.4 %

RXRX stock traded down $0.32 during trading on Friday, hitting $7.02. The company had a trading volume of 5,498,190 shares, compared to its average volume of 6,034,009. The company has a fifty day moving average price of $8.34 and a two-hundred day moving average price of $9.46. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $15.74. The company has a market cap of $1.67 billion, a P/E ratio of -4.39 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The business had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. During the same quarter in the prior year, the firm earned ($0.34) EPS. The firm’s quarterly revenue was up 14.0% compared to the same quarter last year. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.